M1 macrophage-derived exosomal miR-155-5p exacerbates aortic dissection via SMAD5-Mediated regulation of vascular smooth muscle cell phenotype Authors: Dengwei Cao, Xinyi Li, Shaoping Zhu, Jianfeng Chen, Haoxiang Li, Jiajun Shi, Xiaoqi Xiong, Jiahui Liu, Yumou Wang, Zhe Dong, Jiangping Song, Jinping Liu Published: 2026 ABSTRACT AbstractAortic dissection (AD) is a life-threatening cardiovascular emergency characterized by acute aortic wall injury and high mortality, yet effective pharmacological therapies remain limited. Macrophage infiltration and vascular smooth muscle cell (VSMC) phenotypic switching from contractile to synthetic states are central to AD pathogenesis, but the mechanisms mediating intercellular communication between macrophages and VSMCs are incompletely understood. Emerging evidence suggests that exosomes can transfer bioactive miRNAs between cells; however, whether M1 macrophage-derived exosomes promote AD progression through specific miRNA delivery and whether they can be engineered for therapeutic intervention have not been clearly defined. In this study, we demonstrate that M1 macrophage-derived exosomes deliver miR-155-5p to VSMCs, where it targets and suppresses SMAD5, activates the RHOA/ROCK pathway, and drives contractile-to-synthetic phenotypic switching, thereby accelerating AD progression. Through comprehensive physicochemical characterization, including TEM, NTA, Zeta potential, and stability assays, we show that M0 macrophage-derived exosomes can be successfully engineered to load Antago-miR-155-5p via electroporation with favorable encapsulation efficiency and colloidal stability. In a BAPN-induced mouse model of AD, intravenous administration of Antago-miR-155-5p-loaded M0-Exos significantly improved survival, reduced AD incidence and aortic dilation, and restored VSMC contractile markers. Biodistribution studies using DiR and CY5 labeling confirmed efficient accumulation of these engineered exosomes in the injured aorta, while macrophage depletion and rescue experiments validated the pathogenic role of M1-derived exosomes. These findings identify a novel M1 exosome–miR-155-5p–SMAD5/RHOA/ROCK signaling axis in AD and establish engineered M0 macrophage-derived exosomes as a promising bioactive material platform for targeted miRNA therapy in aortic dissection.Keywords: Aortic dissection, Exosomes, miR-155-5p, SMAD5, VSMC phenotypic switching, Bioactive material, Targeted delivery Introduction Aortic dissection (AD) represents a lethal vascular condition involving the architectural degradation of the aortic wall. [1,2]. While operative management persists as the cornerstone of clinical therapy, postoperative mortality is still high. Currently, effective non-surgical strategies for reducing mortality associated with AD are insufficient [[3], [4], [5], [6], [7]]. Therefore, elucidating the mechanisms underlying AD progression, discovering new therapeutic targets, and identifying biomarkers for early diagnosis are crucial for improving early intervention and personalized treatment approaches. Among the various pathological processes involved in AD, inflammation and vascular remodeling are considered central. Accumulating evidence highlights critical roles for inflammatory cell infiltration [8,9], extracellular matrix (ECM) degradation [10], and VSMC phenotypic transition in AD initiation and progression [11,12]. Among the infiltrating inflammatory cells, macrophages are pivotal. Under pathological stimuli such as hypertension, they become activated and often polarize toward the pro-inflammatory M1 phenotype [13,14]. These macrophages further aggravate aortic injury and vascular remodeling through the secretion of inflammatory mediators and matrix metalloproteinases (MMPs), which compromise the structural integrity of the extracellular matrix (ECM) and accelerate AD progression [15,16]. Moreover, inflammatory factors or mechanical stress can prompt VSMCs to switch from contractile to synthetic phenotypes [[17], [18], [19]]. Vascular smooth muscle cell (VSMC) phenotypic switching from a contractile to a synthetic state plays a central role in AD pathogenesis. This transition is accompanied by reduced expression of contractile proteins (e.g., α-SMA, SM22α, MYOCD) and increased proliferation, migration, and extracellular matrix remodeling, ultimately weakening the aortic wall [12]. This phenotypic transition reduces their contractile function while increasing proliferation, migration, and synthetic activities, collectively leading to deterioration of the aortic wall [20]. Notably, intercellular communication between macrophages and VSMCs is vital in AD pathogenesis [21]. Although previous studies suggested that M1 macrophages affect VSMC phenotype switching and vascular integrity [22], the precise molecular mechanisms of this interaction remain unclear. Emerging evidence indicates that exosomes function as essential vehicles for orchestrating cross-talk among cells during cardiovascular disorders by transferring bioactive cargos, including miRNAs, over long distances [[23], [24], [25]]. While macrophage-derived exosomes are known to participate in the pathogenesis of vessel-related disorders, including atherosclerosis and neointimal hyperplasia via miRNAs (e.g., miR-21-3p, miR-222) [26,27], their contribution to AD progression—and in particular the specific miRNA effectors regulating VSMC phenotype in vivo—remains largely unexplored. Notably, Notably, how M1 macrophage-sourced exosomal miRNAs directly regulate the SMAD signaling pathway in VSMCs remains an open question. Our previous work have shown that miR-155-5p can promote VSMC phenotypic switching. In the present study, we demonstrate that M1 macrophage-derived exosomes deliver miR-155-5p to VSMCs, where it directly targets and suppresses SMAD5, leading to activation of the RHOA/ROCK signaling pathway and subsequent synthetic phenotypic transition. This exosome-mediated miR-155-5p/SMAD5/RHOA/ROCK axis significantly accelerates AD progression in vivo. Importantly, we further show that engineered M0 macrophage-derived exosomes loaded with Antago-miR-155-5p can effectively reverse this pathogenic process, restoring SMAD5 expression, maintaining the VSMC contractile phenotype, and attenuating aortic dilation and structural damage in a BAPN-induced mouse model of AD. Through comprehensive physicochemical characterization of exosomes, in vivo biodistribution studies demonstrating aortic targeting, and macrophage-specific validation using depletion and rescue experiments, we provide robust evidence for this novel macrophage–VSMC communication axis. These findings not only uncover a previously unrecognized mechanism by which M1 macrophage-derived exosomes promote AD but also establish M0 macrophage-derived exosomes as a promising platform for targeted miRNA-based therapy in cardiovascular disease. Compared with synthetic delivery systems such as lipid nanoparticles, exosome-based approaches may offer advantages in biocompatibility and natural tissue tropism. Our work provides a strong rationale for further development of exosome-mediated RNA interference strategies as a novel therapeutic approach for aortic dissection. Materials and methods Materials Cell culture and transfection reagents: High-glucose Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS), 0.25% trypsin-EDTA, and 100× penicillin-streptomycin were purchased from Gibco (Thermo Fisher Scientific, Waltham, MA, USA). Lipofectamine 3000 and Opti-MEM™ I Reduced-Serum Medium were obtained from Invitrogen (Thermo Fisher Scientific). miR-155-5p mimics (including FAM-labeled versions), Antago-miR-155-5p, and their negative controls were synthesized by RiboBio Co., Ltd. (Guangzhou, China). The SMAD5-expressing plasmid was provided by Tsingke Biotechnology Co., Ltd. Macrophage polarization and stimulation reagents: Lipopolysaccharide (LPS; catalog no. BS904) and β-aminopropionitrile monofumarate (BAPN; catalog no. S42995) were purchased from Biosharp and Yuanye Bio-Technology (Shanghai, China), respectively. Recombinant mouse interferon-γ (IFN-γ; catalog no. HY-P70610) was obtained from MedChemExpress (Monmouth Junction, NJ, USA). Angiotensin II (Ang II; cat. no. A9525) and GW4869 were purchased from Sigma-Aldrich (Shanghai, China) and MedChemExpress, respectively. The PKH26 Red Fluorescent Cell Linker Kit was obtained from Yu Jiubo Co., Ltd. (Shanghai, China). Antibodies: Primary antibodies against CD9, CD63, TSG101, Calponin (CNN), and iNOS were purchased from Abcam (Cambridge, UK). Antibodies against SM22α, CD68, F4/80, α-SMA, and CD206 were obtained from Proteintech Group, Inc. (Wuhan, China). The anti-MYOCD antibody was purchased from Sigma-Aldrich. Antibodies against SMAD5, E2F2, and SATB1 were provided by ABclonal Technology Co., Ltd. (Wuhan, China). Protease and phosphatase inhibitor cocktails were purchased from Sigma-Aldrich. TRIzol reagent was obtained from Invitrogen. Human aortic tissue collection Human aortic tissue specimens from patients with sporadic aortic dissection and healthy controls were obtained from the institutional biobank of Zhongnan Hospital, Wuhan University. Patients with hereditary aortic diseases (such as Marfan syndrome) or dissections involving the aortic or mitral valves were excluded to ensure cohort homogeneity. Control aortic tissues were collected from age-matched heart transplant donors without any history of aortic aneurysm, dissection, coarctation, or prior aortic surgery. All procedures involving human tissues were conducted in accordance with the Declaration of Helsinki and were approved by the Human Research Ethics Committee of Zhongnan Hospital, Wuhan University (Approval No. 2023187). Written informed consent was obtained from all participants or their legal representatives. Animal model All animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals and were approved by the Animal Care and Use Committee of Zhongnan Hospital, Wuhan University (Approval No. ZN2023009). Three-week-old male C57BL/6 mice were housed under a 12-h light/dark cycle with free access to standard chow and water. To establish the aortic dissection (AD) model, mice were administered β-aminopropionitrile monofumarate (BAPN) in drinking water. For experiments investigating the exacerbating effects of M1 macrophage-derived exosomes, a lower dose of BAPN (0.5 g/kg/day) was used to allow sufficient survival for evaluation of disease progression. For therapeutic intervention studies, including GW4869 treatment, Antago-miR-155-5p-loaded exosome administration, and macrophage depletion experiments, a higher dose of BAPN (1 g/kg/day) was employed to induce more severe disease, thereby facilitating assessment of therapeutic efficacy. Experimental groups and interventions Mice were randomly divided into different experimental groups (n = 15 per group). All treatments were administered every 48 h from week 3 to week 7. GW4869 treatment: Mice in the GW4869 groups were intraperitoneally injected with GW4869 (2.5 μg/g body weight, dissolved in 0.5% DMSO) every 48 h from week 3 to week 7. Control groups received an equal volume of DMSO vehicle. Groups included Saline + DMSO, Saline + GW4869, BAPN + DMSO, and BAPN + GW4869. Exosome administration: Purified M0-Exos or M1-Exos (20 μg protein in 150 μL PBS) were administered via tail vein injection. Groups included Saline + M0-Exos, Saline + M1-Exos, BAPN + M0-Exos, and BAPN + M1-Exos. Antago-miR-155-5p exosome therapy: Engineered M0-derived exosomes loaded with Antago-miR-155-5p or negative control (20 μg protein in 150 μL PBS) were injected via the tail vein in BAPN-treated mice. Macrophage depletion and rescue: Mice received Clodrosome® (macrophage-depleting liposomes) or Encapsome® (control liposomes), with or without subsequent rescue by M1-Exos injection. Isolation and culture of primary VSMCs and BMDMs Primary vascular smooth muscle cells (VSMCs) were isolated from the thoracic aorta of 6–8-week-old male C57BL/6 mice using the explant method. Briefly, the aorta was dissected, and the adventitia and endothelium were carefully removed. The medial layer was cut into small pieces and placed in culture dishes with DMEM containing 20% FBS. Cells migrating from the explants were collected and used between passages 3–6 [28]. Primary bone marrow-derived macrophages (BMDMs) were isolated from the femurs and tibias of 6–8-week-old male C57BL/6 mice. Bone marrow cells were flushed out and cultured in RPMI-1640 medium containing 10% FBS and 20 ng/mL M-CSF for 7 days to differentiate into macrophages. M0 BMDMs were further polarized into M1 phenotype using LPS (100 ng/mL) + IFN-γ (20 ng/mL) for 24 h [29]. Cell culture and macrophage polarization RAW264.7 cells and primary bone marrow-derived macrophages (BMDMs) were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37 °C with 5% CO2. To induce M1 polarization, cells were stimulated with LPS (100 ng/mL) and IFN-γ (20 ng/mL) for 24 h. M0 macrophages were cultured without stimulation. Primary mouse aortic vascular smooth muscle cells (VSMCs) were isolated from the thoracic aorta of C57BL/6 mice using the explant method and cultured in DMEM containing 20% FBS. 1Exosome isolation and purification Exosome isolation and purification M0 or M1 macrophages were cultured in DMEM supplemented with 10% exosome-depleted fetal bovine serum (Catalog No. abs993, Absin) to minimize contamination from bovine exosomes. This commercial exosome-depleted FBS has a reported exosome removal rate of >95% and residual CD63 content <3.125 pg/mL. It is also certified to be mycoplasma-free with low endotoxin levels (<5 EU/mL). Exosomes were isolated from the cell culture supernatant by differential ultracentrifugation. Briefly, the supernatant was sequentially centrifuged at 300 × g for 10 min, 2000 × g for 20 min, and 10,000 × g for 30 min to remove cells and cellular debris. The resulting supernatant was then ultracentrifuged at 100,000 × g for 70 min at 4 °C (Beckman Coulter). The exosome pellet was washed once with PBS and resuspended in PBS. Exosome protein concentration was determined using a BCA protein assay kit. 2Exosome isolation, characterization, and loading Exosome isolation, characterization, and loading Exosomes were isolated from the conditioned medium of M0 or M1 macrophages by differential ultracentrifugation. Western blot analysis was performed to confirm the presence of exosomal markers (CD9, CD63, and TSG101) and the absence of cellular contaminants (Calnexin, GAPDH, Cytochrome C, and GM130). Exosome morphology was examined by transmission electron microscopy (TEM). Particle size distribution and concentration were analyzed by nanoparticle tracking analysis (NTA), and surface charge was determined by Zeta potential measurement using a Zetasizer Nano ZS (Malvern Instruments, UK). For stability assessment, exosomes were incubated in PBS or 10% FBS at 37 °C. At the indicated time points (0, 2, 4, 6, and 8 days), particle size and Zeta potential were re-evaluated by NTA and Zetasizer, respectively. The encapsulation efficiency (EE%) and loading capacity (LC) of Antago-miR-155-5p were quantified by qRT-PCR after electroporation loading and subsequent washing steps. EE% was calculated as: (amount of loaded Antago-miR-155-5p/total input Antago-miR-155-5p) × 100%. Loading capacity was expressed as copies of Antago-miR-155-5p per exosome or per microgram of exosomal protein. 3Loading of Antago-miR-155-5p into exosomes by electroporation Loading of Antago-miR-155-5p into exosomes by electroporation Antago-miR-155-5p was loaded into M0-Exos using electroporation. Briefly, 100 μg of M0-Exos were mixed with 1 nmol Antago-miR-155-5p in electroporation buffer. The mixture was electroporated using a Gene Pulser Xcell system with the following parameters: 400 V, 150 μF, and a single pulse. After electroporation, exosomes were incubated at 37 °C for 30 min to allow membrane recovery and then washed twice with PBS by ultracentrifugation to remove free Antago-miR-155-5p. The encapsulation efficiency was determined by qRT-PCR. 4In vitro exosome uptake and functional assays In vitro exosome uptake and functional assays VSMCs were incubated with PKH26-labeled or FAM-labeled exosomes for 24 h. Cellular uptake was observed by confocal microscopy. For functional studies, VSMCs were treated with M0-Exos, M1-Exos, or Antago-miR-155-5p-loaded M0-Exos. miR-155-5p expression was measured by qRT-PCR. Protein expression of SMAD5 and contractile markers (MYOCD, α-SMA, CNN, SM22α) was analyzed by Western blot. For pathway validation, VSMCs were pretreated with endocytosis inhibitors (sucrose or DMA) or the ROCK inhibitor Y-27632. 1RNA sequencing and bioinformatics analysis RNA sequencing and bioinformatics analysis Total RNA was extracted from VSMCs treated with miR-155OE-Exos or control exosomes. RNA sequencing was performed on an Illumina platform. Differentially expressed genes were analyzed using DESeq2. Gene Ontology (GO) and KEGG pathway enrichment analyses were conducted using clusterProfiler. 2Luciferase reporter assay Luciferase reporter assay The wild-type and mutant 3′-UTR of SMAD5 containing the predicted miR-155-5p binding site were cloned into the pmirGLO vector. VSMCs were co-transfected with luciferase reporter plasmids and miR-155-5p mimic or control. Luciferase activity was measured 48 h post-transfection using the Dual-Luciferase Reporter Assay System. 3Mouse model of aortic dissection and treatments Mouse model of aortic dissection and treatments Three-week-old male C57BL/6 mice were administered β-aminopropionitrile monofumarate (BAPN) dissolved in drinking water to induce AD. A lower dose of BAPN (0.5 g/kg/day) was used in experiments investigating the exacerbating effects of M1 macrophage-derived exosomes. For therapeutic intervention studies, including GW4869 treatment, Antago-miR-155-5p-loaded exosome administration, and macrophage depletion experiments, a higher dose of BAPN (1 g/kg/day) was employed. Mice were randomly divided into different treatment groups. In therapeutic experiments, mice received tail vein injections of Antago-miR-NC-Exos or Antago-miR-155-5p-Exos (20 μg protein in 150 μL PBS) every 48 h from week 3 to week 7. For specificity validation, mice were treated with Clodrosome® with or without M1-Exos rescue. GW4869 was used as a broad-spectrum exosome secretion inhibitor in some experiments. 4Survival analysis and ultrasound imaging Survival analysis and ultrasound imaging Mouse survival was monitored daily. High-frequency ultrasound was performed weekly to measure the maximal aortic diameter. AD incidence and mortality were recorded at the end of the experiment. All mice underwent baseline high-frequency ultrasound measurement of the thoracic aorta at week 3 (prior to BAPN administration). Surviving mice subsequently received weekly ultrasound examinations to monitor maximal aortic diameter. Mice that died before the experimental endpoint (week 7) due to aortic rupture were immediately dissected, and the aorta was photographed alongside a ruler. The maximal aortic diameter was measured from these post-mortem images using ImageJ software. To ensure data completeness, all mice were included in the final assessment of maximal aortic diameter. For mice that died before week 7, the last available measurement (either the final in vivo ultrasound or the post-mortem ImageJ measurement) was used as the endpoint value. It should be noted that measurements obtained from deceased mice using ImageJ may carry potential discrepancies compared with in vivo ultrasound measurements due to post-mortem changes in vascular properties. Histological analysis at the study endpoint was performed on aortic tissues collected either at week 7 (survivors) or immediately after death (non-survivors). 5In vivo biodistribution and imaging In vivo biodistribution and imaging For exosome tracking, DiR-labeled exosomes were injected intravenously into BAPN-treated mice at week 7. In vivo and ex vivo fluorescence imaging was performed at 4 h, 12 h, and 24 h using an IVIS imaging system. To evaluate the pharmacokinetics of the loaded cargo, exosomes containing CY5-labeled Antago-miR-155-5p were administered. At different time points, major organs (heart, liver, spleen, lung, kidney, and aorta) were harvested. Fluorescence intensity was quantified, and the concentration of Antago-miR-155-5p in each organ was measured by qRT-PCR. Pharmacokinetic parameters were calculated based on the time-concentration curves. 6Histological and immunofluorescence analysis Histological and immunofluorescence analysis Aortic tissues were fixed in 4% paraformaldehyde and embedded in paraffin. Sections were stained with hematoxylin and eosin (H&E), Elastic Van Gieson (EVG), and Masson's trichrome. Immunofluorescence staining was performed for SMAD5, SM22α, and macrophage markers (F4/80, iNOS, CD206). Images were captured using a fluorescence microscope and quantified using ImageJ software. 7Blood biochemical analysis Blood biochemical analysis Blood samples were collected at different time points after exosome injection. Hematological parameters (RBC, WBC, PLT, HGB) and biochemical indices (AST, ALT, BUN, CREA) were measured using an automatic biochemical analyzer. 8Quantitative real-time PCR (qRT-PCR) Quantitative real-time PCR (qRT-PCR) Total RNA was extracted using TRIzol reagent according to the manufacturer's instructions. For mRNA detection, cDNA was synthesized using a reverse transcription kit. For miRNA detection, cDNA was synthesized using a miRNA-specific reverse transcription kit. qRT-PCR was performed using SYBR Green Master Mix on a real-time PCR system. Relative expression levels were calculated using the 2−ΔΔCt method, with U6 or GAPDH as the internal reference for miRNA or mRNA, respectively. 9Western blot analysis Western blot analysis Cells or aortic tissues were lysed in RIPA buffer containing protease and phosphatase inhibitors. Equal amounts of protein were separated by SDS-PAGE and transferred onto PVDF membranes. Membranes were blocked with 5% non-fat milk and incubated overnight at 4 °C with primary antibodies. After incubation with HRP-conjugated secondary antibodies, protein bands were visualized using enhanced chemiluminescence (ECL) reagent. Band intensity was quantified using ImageJ software and normalized to GAPDH. 10Statistical analysis Statistical analysis All data are presented as mean ± SD. Statistical analyses were performed using GraphPad Prism software. Survival curves were compared using the Kaplan-Meier method with the log-rank test. Comparisons between two groups were analyzed using unpaired Student's t-test. Multiple group comparisons were performed using one-way or two-way ANOVA followed by Tukey's post hoc test. Pearson's correlation coefficient was used to assess correlations between variables. Blinding and randomization were applied during both experiments and data analysis. A p-value < 0.05 was considered statistically significant. Asterisks denote statistical significance as follows: ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001. Results Accumulation of M1-polarized macrophages and exosomes in aortic dissection (AD) tissue Although exosomes are known mediators of intercellular communication in cardiovascular disease, their role in AD remains poorly understood [30,31]. To comprehensively characterize macrophage infiltration and exosome distribution, multiplex immunofluorescence staining was performed on human and mouse AD tissues using multiple exosome markers in accordance with MISEV2018 guidelines [32]. In human AD tissues, there was marked infiltration of macrophages (CD68+) accompanied by robust expression of exosome markers TSG101 and CD63, with strong co-localization in merged images (Fig. 1A and B). Quantification revealed significantly higher relative fluorescence intensity for CD68, TSG101 and CD63 in AD tissues compared with controls (Fig. S1A, B and Dappsec1). Pearson's correlation coefficient analysis confirmed strong co-localization between exosome markers (TSG101/CD63) and the macrophage marker CD68 in AD lesions (Fig. S1C and E). Accumulation and rigorous characterization of M1 macrophage-derived exosomes in human and mouse aortic dissection (AD) tissues. A–D. Representative multiplex immunofluorescence images showing co-localization of macrophage markers and exosome markers in human (A, B) and mouse (C, D) aortic tissues from control and AD groups. (A, C) DAPI (blue), macrophage marker CD68/F4/80 (green), exosome marker TSG101 (red), and merged images. (B, D) DAPI (blue), exosome marker CD63 (green), TSG101 (red), and merged images. White arrows indicate regions of co-localization. Scale bars: 50 μm (human) and 20 μm (mouse). E–H. Representative immunofluorescence images showing macrophage polarization status in human (E, F) and mouse (G, H) aortic tissues. (E, G) DAPI (blue), macrophage marker CD68/F4/80 (green), M1 marker iNOS (red), and merged images. (F, H) DAPI (blue), macrophage marker CD68/F4/80 (green), M2 marker CD206 (magenta), and merged images. Scale bars as above.Quantification of relative fluorescence intensity and co-localization (Pearson's correlation coefficient) is presented in Supplementary Fig. 1. Data are mean ± SD (n = 3 independent samples per group). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 by unpaired Student's t-test (two-tailed). Similar findings were observed in the BAPN-induced mouse AD model. AD aortas exhibited increased F4/80+ macrophage infiltration and elevated TSG101/CD63 expression with evident co-localization (Fig. 1C and D). Quantitative analysis showed significantly higher fluorescence intensity for F4/80, TSG101 and CD63, together with strong Pearson's correlation coefficients for co-localization in AD versus control tissues (Fig. S1F–H and J). Macrophage polarization was further assessed by double staining for pro-inflammatory M1 (iNOS) and anti-inflammatory M2 (CD206) markers together with macrophage identification markers. In both human and mouse AD tissues, iNOS expression was substantially increased while CD206 was decreased (Fig. 1E–H), indicating a predominant shift toward the M1 phenotype. Quantification confirmed significantly higher iNOS and lower CD206 fluorescence intensity as well as altered co-localization with macrophage markers in AD tissues (Fig. S1K–R). Collectively, these results demonstrate substantial accumulation of M1-polarized macrophages and their derived exosomes in AD tissues from both humans and mice, with close spatial association validated by multiple exosome markers and quantitative co-localization analysis. This spatial proximity suggests that M1 macrophages may contribute to AD progression through exosome-mediated intercellular communication. Inhibition of exosome secretion by GW4869 attenuates BAPN-induced aortic dissection progression in mice To investigate whether inhibition of exosome secretion could attenuate AD progression in vivo, we administered the neutral sphingomyelinase inhibitor GW4869 [33](2.5 μg/g body weight, dissolved in 0.5% DMSO, i.p.) every 48 h to BAPN-treated mice from week 3 to week 7 (Fig. 2A). Kaplan-Meier analysis showed that GW4869 significantly improved survival in BAPN-treated mice compared with vehicle-treated controls (Fig. 2B). Gross examination revealed that BAPN + DMSO mice developed markedly dilated and dissected aortas, whereas GW4869 treatment largely prevented aortic dilation (Fig. 2C). High-frequency ultrasound confirmed that maximal aortic diameter was significantly smaller in the BAPN + GW4869 group than in the BAPN + DMSO group throughout the observation period (Fig. 2D and H). GW4869-mediated inhibition of exosome release attenuates AD progression in a BAPN-induced mouse model. (A). Schematic timeline of the experimental design. Three-week-old male C57BL/6 mice received BAPN (1 g/kg/day) or saline in drinking water from week 3 to week 7. GW4869 (2.5ug/g, i.p.) or vehicle (DMSO) was administered every 48 h starting from week 3. (B). Kaplan-Meier survival curves of mice in the four experimental groups (n = 15 mice per group). ∗P < 0.05 by log-rank test. (C). Representative gross morphological images of whole aortas at the end of the experiment (scale bar = 1 cm). (D). Representative high-frequency ultrasound images of the thoracic aorta. Yellow arrows indicate the aortic lumen diameter. (E). Mortality rates in BAPN-treated mice with or without GW4869 (n = 15 mice per group). (F). Incidence of AD in BAPN-treated mice with or without GW4869 (n = 15 mice per group). (G). Semi-quantitative scoring of elastin fiber degradation in aortic sections (n = 15 mice per group). ∗P < 0.05; ns, not significant. (H). Time-course of maximal aortic diameter measured by ultrasound from week 3 to week 7 (n = 15 mice per group). ∗P < 0.05 by two-way ANOVA with Tukey's post hoc test. (I). Representative histological images of aortic sections stained with H&E, EVG, and Masson's trichrome at week 7. Black arrows in EVG panels indicate fragmented elastic fibers. Scale bars: 200 μm (low magnification) and 20 μm (high magnification insets).Data are presented as mean ± SD (n = 15 mice per group unless otherwise indicated). Survival curves(B) were analyzed using the Kaplan-Meier method followed by log-rank test. Data in (G) and (H) were analyzed by unpaired Student's t-test as appropriate. ∗P < 0.05; ns, not significant. Mortality and AD incidence were also significantly reduced by GW4869 (66.7% vs 33.3% mortality; 86.7% vs 46.7% incidence; Fig. 2E and F). Histological analysis (H&E, EVG, Masson) demonstrated that GW4869 preserved aortic wall architecture, reduced elastic fiber fragmentation (black arrows in EVG), and attenuated medial degeneration in BAPN-treated mice (Fig. 2I). Semi-quantitative scoring confirmed significantly lower elastin degradation grades in the BAPN + GW4869 group compared with BAPN + DMSO (Fig. 2G). No significant effects of GW4869 were observed in saline-treated control mice. Collectively, these results demonstrate that pharmacological inhibition of exosome release with GW4869 significantly attenuates BAPN-induced AD progression, reduces mortality and incidence, and preserves aortic wall integrity in mice. This suggests that macrophage-derived exosomes play a critical pathogenic role in AD development. Characterization and purification of extracellular vesicles from macrophages To investigate the role of macrophage-derived exosomes in AD, we first optimized M1 polarization conditions in RAW264.7 cells. Macrophages were stimulated with LPS (100 ng/mL) combined with increasing concentrations of IFN-γ (2.5–20 ng/mL). This dose-response experiment was performed to determine the optimal stimulation condition that maximally induces M1 polarization, as reflected by the highest iNOS expression (Fig. 3A and C). At the optimal concentrations of LPS (100 ng/mL) and IFN-γ (20 ng/mL), iNOS expression was significantly upregulated. Western blot analysis further confirmed successful M1 polarization (Fig. 3B and D). Morphologically, M1-polarized macrophages displayed multipolar extensions, in contrast to the smaller and rounder morphology of control cells (Fig. 3E). Polarization of RAW264.7 macrophages to M1 phenotype and characterization of derived exosomes. (A). Western blot analysis of iNOS expression in RAW264.7 macrophages treated with LPS (100 ng/mL) plus increasing concentrations of IFN-γ (2.5–20 ng/mL). GAPDH was used as a loading control. (B). Western blot confirmation of iNOS expression in RAW264.7 macrophages under optimal polarization conditions (LPS 100 ng/mL + IFN-γ 20 ng/mL). (C). Quantification of relative iNOS protein expression from panel A (n = 3 independent experiments). (D). Quantification of relative iNOS protein expression from panel B (n = 3 independent experiments). (E). Representative bright-field images showing morphological changes in RAW264.7 macrophages after PBS or LPS + IFN-γ treatment. Scale bar = 100 μm. (F). Western blot analysis of exosomal markers (CD9, CD63, TSG101) and negative markers (Calnexin, GAPDH, Cytochrome C, GM130) in M0-Exos, M1-Exos, and corresponding cell lysates. (G). Transmission electron microscopy (TEM) images of M0-Exos and M1-Exos showing typical cup-shaped morphology with bilayer membranes. Scale bars: 500 nm, 200 nm, and 100 nm. (H–I). Nanoparticle tracking analysis (NTA) showing size distribution and concentration of M0-Exos (H) and M1-Exos (I), with peak diameters around 100 nm. Mean ± SEM. Data in (C) and (D) were analyzed via unpaired Student t-test. ∗P < 0.05, ∗∗∗P < 0.001. Exosomes were then isolated from the conditioned medium of M0 (M0-Exos) and M1 (M1-Exos) macrophages by ultracentrifugation. Western blot analysis showed high enrichment of exosomal markers CD9, CD63, and TSG101 in both M0-Exos and M1-Exos, with no detectable contamination by the ER marker Calnexin, cytoplasmic marker GAPDH, mitochondrial marker Cytochrome C, or Golgi marker GM130 (Fig. 3F). Transmission electron microscopy revealed typical cup-shaped morphology with bilayer membranes and a mean diameter of approximately 100 nm for both exosome populations (Fig. 3G). Nanoparticle tracking analysis corroborated these findings, showing peak size distributions around 100 nm for M0-Exos and M1-Exos (Fig. 3H and I). Although RAW264.7 cells were primarily used for large-scale exosome production due to their high yield required for subsequent in vivo studies, we further validated the key findings using primary bone marrow-derived macrophages (BMDM). LPS + IFN-γ stimulation was applied to induce M1 polarization in BMDM, and the results were consistent with those obtained from RAW264.7 cells, as evidenced by significantly increased iNOS expression (Fig. S1A and B). Exosomes were subsequently isolated from these polarized BMDM and subjected to the same downstream in vitro functional assays to confirm the consistency of their effects with those of RAW264.7-derived exosomes. Collectively, these characterizations validate the successful generation of M1-polarized macrophages and isolation of high-purity exosomes, setting the foundation for evaluating their functional impact on AD progression. Exosomes derived from M1 macrophages promote phenotypic transition of vascular smooth muscle cells (VSMCs) In the pathogenesis of AD, intercellular crosstalk between macrophages and VSMCs plays a pivotal role, with exosomes potentially serving as key mediators, and VSMC phenotypic switching from contractile to synthetic states being essential for disease initiation and progression [12,[34], [35], [36], [37]]. To investigate whether M1 macrophage-derived exosomes promote phenotypic switching of VSMCs, primary mouse aortic VSMCs were treated with exosomes isolated from M0-or M1-polarized RAW264.7 macrophages. Confocal microscopy confirmed efficient uptake of PKH26-labeled M1-Exos by VSMCs (Fig. 4B). Western blot analysis showed that M1-Exos significantly downregulated the expression of contractile markers (MYOCD, α-SMA, CNN, and SM22α) compared with M0-Exos (Fig. 4C and D). Consistent results were obtained at the mRNA level by qRT-PCR (Fig. 4E–H). Exosomes from M1 macrophages induce vascular smooth muscle cells (VSMCs) phenotypic switching. (A). Representative immunofluorescence images of primary mouse aortic VSMCs stained for α-SMA (green) and nuclei (blue). Scale bar = 25 μm. (B). Confocal microscopy images showing uptake of PKH26-labeled M0-Exos and M1-Exos (red) by VSMCs. VSMCs were stained with 488-phalloidin (green) for F-actin and Hoechst 33342 (blue) for nuclei. Scale bar = 25 μm. (C). Western blot analysis of contractile markers (MYOCD, α-SMA, CNN, SM22α) in VSMCs treated with M0-Exos or M1-Exos. GAPDH was used as a loading control. (D). Densitometric quantification of protein expression from panel C (n = 3 independent experiments). (E–H). Quantitative real-time PCR analysis of mRNA levels of contractile markers in VSMCs treated with M0-Exos or M1-Exos (n = 3 independent experiments). (I). Schematic diagram of the non-contact Transwell co-culture system. RAW264.7 macrophages (M0 or M1) were seeded in the upper chamber, and VSMCs were cultured in the lower chamber with or without GW4869 (20 μM). (J). Western blot analysis of contractile markers in VSMCs after co-culture with M0 or M1 macrophages in the presence or absence of GW4869. (K–N). Quantification of relative protein expression from panel J (n = 3 independent experiments). Data in D through H was analyzed using unpaired Student's t-test. Data in K through N was analyzed using a two-way ANOVA followed by Tukey post hoc test. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001; ns, not significant. To further confirm that these effects were exosome-dependent, a non-contact Transwell co-culture system was established (Fig. 4I). M1-polarized RAW264.7 macrophages significantly suppressed contractile marker expression in VSMCs, whereas addition of the exosome secretion inhibitor GW4869 (20 μM) partially restored their expression without affecting M0 macrophage co-cultures (Fig. 4J–N). To enhance physiological relevance, parallel experiments were performed using primary bone marrow-derived macrophages (BMDM). Exosomes isolated from M1-polarized BMDM similarly downregulated contractile markers in VSMCs (Fig. S3A–C), and GW4869 treatment in the co-culture system also partially reversed these effects (Fig. S3D–I). Collectively, these results demonstrate that M1 macrophage-derived exosomes promote VSMC phenotypic switching from a contractile to a synthetic phenotype in an exosome-dependent manner, supporting a critical role of this intercellular communication in AD pathogenesis. In vivo biodistribution and aortic targeting of DIR-labeled M0-and M1-derived exosomes in BAPN-induced AD mice To address the biodistribution and uptake of exosomes in the injured aorta, DIR-labeled M0-Exos and M1-Exos were intravenously administered to BAPN-induced AD mice at week 7. Ex vivo IVIS imaging of the aorta was performed at 4 h, 12 h, and 24 h after injection (Fig. 5A). Strong fluorescent signals were detected in the aortic tissue of both M0-Exos-DIR and M1-Exos-DIR groups, with the signal intensity increasing from 4 h and peaking at 12 h post-injection (Fig. 5B). Quantitative analysis confirmed that aortic fluorescence intensity in both exosome groups was significantly higher than that in the saline control at all examined time points, with the highest accumulation observed at 12 h (Fig. 5C). In vivo biodistribution and aortic targeting of DIR-labeled M0-and M1-derived exosomes in BAPN-induced AD mice. (A). Schematic timeline of the experimental design. BAPN-treated mice received tail vein injection of DIR-labeled M0-Exos or M1-Exos at week 7, followed by IVIS imaging at 4 h, 12 h, and 24 h post-injection. (B). Representative in vivo whole-body and ex vivo organ IVIS images showing fluorescence distribution at 4 h, 12 h, and 24 h after injection of saline, M0-Exos-DIR, or M1-Exos-DIR. The left panel shows ex vivo imaging of the aorta at different time points. (C). Quantitative analysis of whole-body fluorescence intensity at different time points after exosome injection (n = 3 mice per group). (D–F). Quantitative analysis of fluorescence intensity in major organs (heart, liver, spleen, lung, and kidney) at 4 h (D), 12 h (E), and 24 h (F) after injection (n = 3 mice per group). Data are presented as mean ± SD. Statistical significance was unpaired Student t-test. ∗∗∗∗P < 0.0001 vs. Saline; ####P < 0.0001 vs. Saline by unpaired Student's t-test. Although the liver and spleen showed the strongest overall signals, clear fluorescent accumulation was also observed in the aorta (Fig. 5B and D–F), indicating that macrophage-derived exosomes can effectively reach and be retained in the injured aortic tissue. Notably, M0-and M1-derived exosomes exhibited comparable aortic distribution patterns. These findings demonstrate that DIR-labeled exosomes possess favorable biodistribution properties and can target the pathological aorta in the AD model, providing important pharmacokinetic support for their therapeutic potential. M1-derived exosomes exacerbate BAPN-induced AD progression and promote phenotypic switching in VSMCs To further investigate the role of M1 macrophage-derived exosomes in AD progression, exosomes isolated from M1-polarized (M1-Exos) or M0-polarized (M0-Exos) RAW264.7 macrophages were administered to BAPN-treated mice via tail vein injection every 48 h from week 3 to week 7 (Fig. 6A). M1-Exos treatment significantly worsened survival compared with M0-Exos (Fig. 6B). Gross morphological examination revealed more severe aortic dilation and lesion formation in the BAPN + M1-Exos group (Fig. 6C). High-frequency ultrasound confirmed that maximal aortic diameter was significantly larger in mice receiving M1-Exos (Fig. 6D and H). In addition, M1-Exos administration markedly increased both mortality and AD incidence compared with M0-Exos (Fig. 6E and F). Histological analysis (H&E, EVG, Masson) demonstrated that M1-Exos exacerbated aortic wall damage, including greater luminal expansion, more severe elastic fiber fragmentation (Fig. 6G). (black arrows in EVG), and increased collagen deposition (Fig. 6I). Western blot analysis of aortic tissues further showed that M1-Exos significantly downregulated the expression of contractile markers (MYOCD, α-SMA, CNN, and SM22α) compared with M0-Exos (Fig. 6J and K). M1 macrophage-derived exosomes exacerbate BAPN-induced aortic dissection progression in mice. (A). Schematic timeline of the experimental design. BAPN-treated mice received tail vein injections of M0-Exos or M1-Exos (20 μg protein/150 μL) every 48 h from week 3 to week 7. (B). Kaplan-Meier survival curves (n = 15 mice per group). (C). Representative gross morphological images of whole aortas at week 7 (scale bar = 1 cm). (D). Representative high-frequency ultrasound images of the thoracic aorta. Yellow arrows indicate the aortic lumen. (E). Mortality rates in BAPN-treated mice (n = 15 mice per group). (F). Incidence of AD in BAPN-treated mice (n = 15 mice per group). (G). Semi-quantitative scoring of elastin fiber degradation (n = 15 mice per group). (H). Time course of maximal aortic diameter measured by ultrasound from week 3 to week 7 (n = 15 mice per group). (I). Representative histological images of aortic sections stained with H&E, EVG, and Masson's trichrome at week 7. Black arrows in EVG panels indicate fragmented elastic fibers. Scale bars: 200 μm (low magnification) and 20 μm (high-magnification insets). (J). Western blot analysis of contractile markers (MYOCD, α-SMA, CNN, SM22α) in aortic tissues from BAPN + M0-Exos and BAPN + M1-Exos groups. (K). Quantification of relative protein expression from panel J (n = 3 independent experiments). Data are presented as mean ± SD. The survival curves in B were analyzed using the Kaplan-Meier curve and compared using the log-rank test. Data in G, H and K was analyzed via unpaired Student t-test. ∗P < 0.05, ∗∗P < 0.01; ns, not significant. These results demonstrate that M1 macrophage-derived exosomes aggravate BAPN-induced AD progression by promoting VSMC phenotypic switching and aortic wall destruction, highlighting their pathogenic role in AD. Macrophage depletion attenuates BAPN-induced AD progression, which is reversed by M1-derived exosome supplementation Although GW4869 is a broad-spectrum neutral sphingomyelinase inhibitor that blocks exosome release from multiple cell types in vivo, the protective effects observed with GW4869 treatment indicate that inhibition of exosome secretion is beneficial in AD. However, these data do not establish the specific contribution of macrophages. To address this limitation and determine the role of M1 macrophages and their derived exosomes more specifically, we employed a standard macrophage depletion strategy using Clodrosome® (clodronate liposomes) in combination with Encapsome® (control liposomes) [38], with or without supplementation of M1-Exos (Fig. 7A). Macrophage depletion attenuates BAPN-induced AD progression, which is reversed by supplementation with M1-derived exosomes. (A). Schematic timeline of the experimental design. BAPN-treated mice received tail vein injections of Encapsome® (control liposomes), Clodrosome® (macrophage-depleting liposomes), or M1-Exos every 48h from week 3 to week 7. (B). Kaplan-Meier survival curves (n = 15 mice per group). (C). Representative gross morphological images of whole aortas at week 7 (scale bar = 1 cm). (D). Representative high-frequency ultrasound images of the thoracic aorta. Yellow arrows indicate the aortic lumen. (E). Time course of maximal aortic diameter measured by ultrasound from week 3 to week 7 (n = 15 mice per group). (F)). Mortality rates (n = 15 mice per group). (G). Incidence of AD (n = 15 mice per group). (H). Semi-quantitative scoring of elastin fiber degradation (n = 15 mice per group). (I). Representative histological images of aortic sections stained with H&E, EVG, and Masson's trichrome at week 7. Black arrows in EVG panels indicate fragmented elastic fibers. Scale bars: 200 μm (low magnification) and 20 μm (high-magnification insets). Data are presented as mean ± SD. Survival curves (B) were analyzed by Kaplan-Meier method with log-rank test. Other data were analyzed by two-way ANOVA followed by Tukey's post hoc test or unpaired Student's t-test. ∗P < 0.05; ns, not significant. Macrophage depletion with Clodrosome® significantly improved survival compared with Encapsome®-treated controls (Fig. 7B). Gross morphological examination and ultrasound imaging showed that Clodrosome® markedly reduced aortic dilation and lesion severity, whereas supplementation with M1-Exos largely reversed this protective effect (Fig. 7C–E). Quantitative analysis further demonstrated that macrophage depletion significantly lowered both mortality and AD incidence, while M1-Exos administration restored high levels of mortality and AD incidence (Fig. 7F and G). Histological assessment (H&E, EVG, Masson) revealed that Clodrosome® preserved aortic wall integrity and reduced elastic fiber fragmentation, whereas M1-Exos supplementation aggravated structural damage (Fig. 7I). Elastin degradation scoring confirmed that macrophage depletion significantly alleviated elastin breakdown, which was reversed by M1-Exos (Fig. 7H). These results demonstrate that depletion of macrophages attenuates BAPN-induced AD progression, while replenishment with M1 macrophage-derived exosomes reverses this protective effect. This provides direct evidence that M1-derived exosomes play a critical pathogenic role in AD development. miR-155-5p is enriched in M1 macrophage-derived exosomes and internalized by VSMCs primarily via macropinocytosis Exosomes mediate intercellular communication by transporting bioactive cargo such as miRNAs, thereby influencing cellular signaling and contributing to disease pathogenesis. [39]. Given previous findings that M1-Exos exacerbate AD, we sought to identify the key functional exosomal components responsible for this effect. we conducted miRNA sequencing on exosomes from M1-and M0-polarized RAW264.7 macrophages, complemented by analysis of public datasets. Heatmap visualization based on sequencing data of exosomes derived from M0 and M1 macrophages showed the upregulation of specific miRNAs in M1 cells, including a prominent increase in miR-155-5p (Fig. 8A). Volcano plots from our exosomal sequencing highlighted differentially expressed miRNAs, with miR-155-5p markedly upregulated in M1-Exos (Fig. S4A). Integration with GSE125171 (BMDMs) revealed consistent patterns: heatmaps and volcano plots showed miR-155-5p among top upregulated miRNAs in M1-BMDMs (Fig. S4B and C). Our cellular sequencing of RAW264.7 similarly identified miR-155-5p enrichment in M1 states via heatmaps and volcano plots (Fig. S4D and E). A Venn diagram cross-referencing predicted targets, GSE125171 differentials, and our exosomal miRNAs pinpointed miR-155-5p as the overlapping hit (Fig. 8B). Therefore, we hypothesized that M1-Exos accelerate AD by transferring miR-155-5p to VSMCs and inducing a synthetic phenotype. miR-155-5p is enriched in M1 macrophage-derived exosomes and internalized by VSMCs primarily via macropinocytosis. (A). Heatmap of differentially expressed miRNAs in M0-and M1-polarized RAW264.7 cells and their derived exosomes. (B). Venn diagram showing the overlap of upregulated miRNAs among RAW264.7 cells, BMDMs, and exosomes, highlighting miR-155-5p. (C–D). qRT-PCR analysis of miR-155-5p expression in M0-and M1-polarized RAW264.7 cells (C) and their derived exosomes (D) (n = 3 independent experiments). (E–F). qRT-PCR analysis of miR-155-5p expression in mouse (E) and human (F) aortic tissues (Control vs. AD) (n = 3 samples per group). (G–H). FISH detection of miR-155-5p in mouse (G) and human (H) aortic tissues (Control vs. AD). Scale bars = 20–50 μm. (I). Confocal images showing co-localization of PKH26-labeled exosomes (red) and FAM-labeled miR-155-5p (green) in VSMCs. Nuclei were stained with Hoechst 33342 (blue). Scale bar = 25 μm. (J). Quantification of relative miR-155-5p uptake in VSMCs treated with M0-Exos or M1-Exos (n = 3 independent experiments). (K). Confocal images showing the effect of endocytosis inhibitors (Sucrose and DMA) on the uptake of FAM-miR-155-5p-labeled exosomes by VSMCs. Scale bar = 25 μm. (L). Quantification of mean fluorescence intensity from panel K (n = 3 independent experiments). (M). qRT-PCR analysis of miR-155-5p levels in VSMCs after treatment with RNase A or RNase A + Triton X-100 (n = 3 independent experiments). N. Western blot analysis of contractile markers (MYOCD, α-SMA, CNN, SM22α) in VSMCs treated with PBS, miR-NC^OE-Exos, or miR-155^OE-Exos. GAPDH was used as a loading control. (O). qRT-PCR analysis of miR-155-5p expression in RAW264.7 macrophages after transfection with miR-NCOE or miR-155OE (n = 3 independent experiments). (P). qRT-PCR analysis of miR-155-5p expression in exosomes derived from miR-NCOE or miR-155OE transfected RAW264.7 macrophages (n = 3 independent experiments). (Q–R). FISH quantification of miR-155-5p in mouse (Q) and human (R) aortic tissues (Control vs. AD). Data are presented as mean ± SD. Data (L) and (M) was analyzed using a two-way ANOVA followed by Tukey post hoc test. Data from other experiments were analyzed using an unpaired Student's t-test. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001; ns, not significant. qRT-PCR validation confirmed that miR-155-5p was significantly upregulated in M1-polarized RAW264.7 cells and their exosomes, as well as in primary BMDMs and BMDM-derived exosomes (Fig. 8C–D and Fig. S5A–B). Elevated miR-155-5p expression was also verified in both mouse and human AD aortic tissues compared with controls by qRT-PCR (Fig. 8E and F) and RNA-FISH (Fig. 6G and H and 8Q-R). To determine whether M1-Exos deliver miR-155-5p to VSMCs, we transfected M1 macrophages with FAM-labeled miR-155-5p mimics and isolated exosomes. Confocal microscopy showed co-localization of PKH26-labeled exosomes (red) and FAM-miR-155-5p (green) inside VSMCs (Fig. 8I). qRT-PCR confirmed increased miR-155-5p levels in recipient VSMCs. Pretreatment of exosomes with Triton X-100 (membrane disruption) followed by RNase A digestion markedly reduced miR-155-5p transfer, whereas RNase A alone had minimal effect, indicating that exosomal encapsulation protects miR-155-5p from degradation (Fig. 8M). To determine the endocytic pathway mediating this uptake, VSMCs were pretreated with pharmacological inhibitors [26]. Pretreatment with DMA (a macropinocytosis inhibitor) significantly reduced the internalization of FAM-miR-155-5p-labeled exosomes, whereas sucrose (a clathrin-mediated endocytosis inhibitor) had no significant effect (Fig. 8K and L). These results indicate that macropinocytosis is the primary pathway mediating the uptake of miR-155-5p-containing exosomes into VSMCs. To assess the functional role of exosomal miR-155-5p, we generated miR-155-5p-overexpressing exosomes (miR-155OE-Exos) from both RAW264.7 and primary BMDM. qRT-PCR confirmed successful overexpression in cells and exosomes (Fig. 8L–M and Fig. S7A–B). Incubation of VSMCs with miR-155OE-Exos from either source significantly downregulated contractile markers (MYOCD, α-SMA, CNN, SM22α) compared with control exosomes, as shown by Western blot and quantification (Fig. 8N and Fig. S6A–D, S7C–G). Collectively, these results demonstrate that miR-155-5p is enriched in M1 macrophage-derived exosomes from both cell lines(RAW264.7) and primary cells(BMDM), protected from degradation during transfer, and functionally promotes VSMC phenotypic switching, thereby contributing to AD progression. miR-155-5p negatively regulates SMAD5 expression to control VSMC phenotypic switching To uncover the downstream mechanism by which exosomal miR-155-5p induces VSMC dedifferentiation, we integrated RNA-seq data from treated VSMCs with miRNA target prediction databases (miRDB and TargetScan). Venn analysis revealed 17 overlapping differentially expressed mRNAs (Fig. 9A). Network mapping prioritized SMAD5 as a high-confidence target with strong connectivity (Fig. 9B). Enrichment analysis showed these candidates were involved in transcriptional regulation, protein phosphorylation, angiogenesis, and morphological transformation, relevant to AD pathogenesis (Fig.S8A-C). GO enrichment analysis of DEGs in miR-155OE-Exos-treated VSMCs revealed significant overrepresentation of terms related to transcription factor activity, DNA-binding regulation, and cell homeostasis (Fig. S9A), further supporting a role in transcriptional reprogramming during phenotypic switching. SMAD5 is directly targeted by miR-155-5p and mediates VSMC phenotypic transition in AD. (A). Venn diagram showing the overlap of differentially expressed mRNAs from RNA-seq of miR-155OE-Exos-treated VSMCs with predicted targets from miRDB and TargetScan databases, identifying 17 candidate genes. (B). Protein-protein interaction network of the 17 candidate target genes of miR-155-5p, with SMAD5 highlighted as a central node. (C). Schematic workflow for target identification and validation. (D–E). Representative immunofluorescence images of SMAD5 (green) and SM22α (red) in human (D) and mouse (E) aortic tissues (Control vs. AD). Scale bars = 50–100 μm. (F–I). Quantification of relative fluorescence intensity of SMAD5 and SM22α in human and mouse aortic tissues (n = 3 samples per group). (J). Schematic of the predicted miR-155-5p binding site in the SMAD5 3′-UTR and mutant sequence. (K). Dual-luciferase reporter assay confirming direct targeting of SMAD5 3′-UTR by miR-155-5p (n = 3 independent experiments). (L). Western blot analysis of SMAD5 in VSMCs treated with miR-NCOE-Exos or miR-155OE-Exos. (M). Western blot analysis of contractile markers and SMAD5 in VSMCs treated with miR-155OE-Exos, with or without SMAD5 overexpression. Data are presented as mean ± SD. Data (K) was analyzed using a two-way ANOVA followed by Tukey post hoc test. Data from other experiments were analyzed using an unpaired Student's t-test. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001; ns, not significant. We next systematically screened all 17 candidate genes in primary VSMCs treated with miR-155OE-Exos versus miR-NCOE-Exos using qRT-PCR. Among them, six genes (SMAD5, E2F2, STAB1, PICALM, KDM3A, and SDCBP) showed consistent and significant downregulation (Fig. S9N–S), while the remaining candidates exhibited no significant or inconsistent changes (Fig. S9C–M). These six genes were therefore prioritized for further validation. Tissue-level validation in both human and mouse AD aortic tissues confirmed significant downregulation of SMAD5, STAB1, and E2F2 at the mRNA level. Validation pipeline combined qRT-PCR for mRNA candidates in treated VSMCs and AD tissues, followed by protein confirmation via WB in human and mouse AD samples (Fig. 9C). Among candidates, SMAD5 showed consistent downregulation (Fig. S10 and S11). Previous studies have demonstrated that SMAD5 plays a critical role in regulating vascular smooth muscle cell phenotypic switching through the TGF-β/BMP signaling pathway [40]. Immunofluorescence staining further demonstrated markedly reduced SMAD5 and SM22α expression with diminished co-localization in AD aortic walls (Fig. 9D and E), and quantitative analysis confirmed significant downregulation of both proteins (Fig. 9F–I). TargetScan bioinformatic predictions and dual-luciferase assays provided evidence confirming direct interaction of miR-155-5p with the SMAD5 3′-UTR region (Fig. 9J and K). To further establish the functional consequence of this interaction in the context of exosomal delivery, primary VSMCs were treated with exosomes derived from miR-155-overexpressing RAW264.7 cells (miR-155OE-Exos). Immunoblot analysis further demonstrated reduced SMAD5 protein levels upon miR-155-5p upregulation (Fig. 9L and Fig. S12A). Importantly, rescue experiments showed that SMAD5 overexpression largely restored the expression of these contractile markers suppressed by miR-155OE-Exos, whether the exosomes were derived from RAW264.7 cells or primary BMDM (Fig. 9M and M and Fig. S12B-F and Fig. S13). These findings indicate that SMAD5 mediates the phenotypic switching effect of miR-155-5p and that this mechanism is consistent between cell line-derived and primary macrophage-derived exosomes, indicating that SMAD5 restoration can largely rescue the phenotypic switching induced by miR-155OE-Exos. Collectively, these results demonstrate that exosomal miR-155-5p directly targets SMAD5 to induce synthetic phenotypic switching in VSMCs, thereby contributing to AD progression. SMAD5 restoration largely reverses this effect, highlighting SMAD5 as a key downstream mediator. SMAD5 regulates VSMC phenotypic switching via the RHOA/ROCK pathway To further elucidate the mechanism by which SMAD5 mediates miR-155-5p-induced VSMC phenotypic switching, we performed RNA sequencing on VSMCs treated with miR-155^OE-Exos versus miR-NCOE-Exos, as well as on VSMCs treated with miR-155OE-Exos plus SMAD5 overexpression versus control plasmid. Transcriptomic analysis revealed that miR-155-5p overexpression significantly downregulated contractile genes (MYOCD), while SMAD5 overexpression largely reversed these transcriptional changes (Fig. 10A and D). SMAD5 regulates VSMC phenotypic switching via the RHOA/ROCK pathway. (A–C). RNA-seq, GO enrichment, and KEGG pathway analysis of VSMCs treated with miR-NCOE-Exos versus miR-155OE-Exos. (D–F). RNA-seq, GO enrichment, and KEGG pathway analysis of VSMCs treated with miR-155OE-Exos + SMAD5NC versus miR-155OE-Exos + SMAD5OE. (G). Western blot analysis of the RHOA/ROCK pathway (p-MYPT1, p-MLC) and contractile markers in VSMCs treated with miR-NCOE-Exos, miR-155OE-Exos, miR-155OE-Exos + SMAD5NC, or miR-155OE-Exos + SMAD5OE. (H–J). Quantification of relative protein expression from panel G (n = 3 independent experiments). (K). Western blot analysis of VSMCs treated with miR-155OE-Exos ± SMAD5OE in the presence or absence of the ROCK inhibitor Y-27632 (10 μM).Data are presented as mean ± SD (n = 3 independent experiments). Data are presented as mean ± SD. Data was analyzed using a two-way ANOVA followed by Tukey post hoc test. Data from other experiments were analyzed using an unpaired Student's t-test. ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001; ns, not significant. GO and KEGG enrichment analyses of differentially expressed genes from both RNA-seq datasets consistently showed significant enrichment in pathways related to actin cytoskeleton organization, focal adhesion, vascular smooth muscle contraction, and tight junction (Fig. 10B and C and Fig. 10E and F). These biological processes are well-known to be regulated by the RHOA/ROCK signaling pathway. Western blot analysis further confirmed that treatment with miR-155-5p-overexpressing exosomes led to increased phosphorylation of MYPT1 and MLC (downstream targets of ROCK), which was reversed by SMAD5 overexpression (Fig. 10G–J). Moreover, pharmacological inhibition of ROCK with Y-27632 abolished the ability of SMAD5 overexpression to rescue contractile marker expression (Fig. 10K and Fig. S14), indicating that the RHOA/ROCK pathway functions downstream of SMAD5 in regulating VSMC phenotype. It is well established that activation of the RHOA/ROCK pathway promotes VSMC phenotypic switching from a contractile to a synthetic state by modulating cytoskeletal dynamics and suppressing the expression of contractile proteins. Our integrated transcriptomic and functional data suggest that SMAD5 regulates VSMC phenotypic switching, at least in part, through modulation of the RHOA/ROCK signaling axis. Comprehensive physicochemical characterization and in vivo biodistribution of Antago-miR-155-5p-loaded M0 macrophage-derived exosomes To develop an effective therapeutic strategy targeting exosomal miR-155-5p in AD, we engineered M0 macrophage-derived exosomes loaded with Antago-miR-155-5p. M0 macrophage-derived exosomes were chosen as the delivery platform because they possess low immunogenicity and minimal pro-inflammatory properties compared with M1-derived exosomes. This characteristic is particularly advantageous in the AD model, where excessive inflammation can exacerbate disease progression. Additionally, M0-Exos exhibit excellent biocompatibility, efficient cellular uptake, and favorable in vivo stability, making them suitable carriers for nucleic acid therapeutics such as antagomirs. We first conducted comprehensive physicochemical characterization of the engineered exosomes. Western blot analysis confirmed that loading of Antago-miR-155-5p did not alter the expression of typical exosomal markers (CD9, CD63, TSG101) and did not introduce contamination from cellular organelles (Fig. 11A). Transmission electron microscopy demonstrated that both unloaded and Antago-miR-155-5p-loaded M0-Exos maintained typical cup-shaped morphology with intact bilayer membrane structures (Fig. 11B). Nanoparticle tracking analysis showed that the average size of M0-Exos was approximately 150 nm before and after loading, with no significant change in surface charge (Zeta potential) (Fig. 11C and D). The engineered exosomes also maintained good colloidal stability when incubated in PBS or 10% FBS for up to 7 days (Fig. 11E and F). Quantitative analysis revealed that the encapsulation efficiency (EE) and loading capacity (LC) of Antago-miR-155-5p reached 48.6 ± 6.2% and 712 ± 89 copies/μg exosomal protein, respectively (Fig. 11G and H). Comprehensive physicochemical characterization and in vivo biodistribution of Antago-miR-155-5p-loaded M0 macrophage-derived exosomes. A. Western blot analysis of exosomal markers (CD9, CD63, TSG101) and negative markers (Calnexin, GAPDH, Cytochrome C, GM130) in M0 cells and M0-Exos before and after Antago-miR-155-5p loading. B. Transmission electron microscopy (TEM) images of M0-Exos before and after Antago-miR-155-5p loading. Scale bars: 500 nm, 200 nm, and 100 nm. C–F. Nanoparticle tracking analysis (NTA) showing size distribution (∼150 nm) and Zeta potential stability of M0-Exos before and after loading in PBS and 10% FBS. G–H. Encapsulation efficiency (EE%) and loading capacity (LC) of Antago-miR-155-5p into M0-Exos (n = 3 independent experiments). I. Schematic timeline of the in vivo biodistribution study. J. Representative in vivo whole-body and ex vivo organ/aorta IVIS images of DIR-labeled M0-Exos, Antago-miR-NC-Exos-DIR, and Antago-miR-155-5p-Exos-DIR at 4 h, 12 h, and 24 h post-injection. The left panel shows ex vivo aorta imaging. K. Quantitative analysis of whole-body fluorescence intensity at different time points (n = 3 mice per group). L. Organ-specific fluorescence intensity at 4 h and 24 h, and time-course concentration of Antago-miR-155-5p in major organs (n = 3 mice per group). Data are presented as mean ± SD (n = 3 independent experiments). Statistical significance was unpaired Student t-test. ∗∗∗∗P < 0.0001 vs. M0-Exos; ####P < 0.0001 vs. M0-Exos by unpaired Student's t-test. To evaluate the in vivo targeting capability and biodistribution of the engineered exosomes, we performed IVIS imaging using DIR-labeled Antago-miR-155-5p-Exos in BAPN-induced AD mice. Ex vivo imaging of the aorta at 4 h, 12 h, and 24 h post-injection clearly demonstrated detectable fluorescent signals in the aortic tissue, with signal intensity increasing from 4 h and remaining visible at 24 h (Fig. 11J, left panel). This result confirmed that the engineered exosomes could effectively reach and accumulate at the target site — the injured aorta. Whole-body and major organ imaging further showed predominant accumulation in the liver and spleen, with sustained signals detectable up to 24 h (Fig. 11J, right panel). Quantitative analysis indicated that fluorescence intensity peaked at 12 h post-injection and remained significantly higher than background levels at 24 h in both M0-Exos and Antago-miR-155-5p-Exos groups (Fig. 11K). Organ-specific quantification and pharmacokinetic analysis revealed efficient accumulation of Antago-miR-155-5p in the aorta as well as other major organs, with a gradual decline over 72 h and no obvious off-target toxicity (Fig. 11L). Organ-specific quantification further demonstrated that both M0-Exos and Antago-miR-155-5p-Exos accumulated efficiently in the aorta as well as in major organs including the liver and spleen. At 4 h, 12 h, and 24 h post-injection, fluorescence intensity in the liver and spleen was significantly higher than in other organs (heart, lung, and kidney), while clear signals were also detectable in the aorta (Fig. 11L and Fig. S15A–C). Time-course pharmacokinetic analysis revealed that Antago-miR-155-5p concentration (copies/μg total RNA) in major organs peaked between 4 h and 12 h post-injection and gradually declined over 72 h, with the liver exhibiting the highest accumulation, followed by the spleen and aorta (Fig. 11L and Fig. S15D). Importantly, no significant off-target toxicity was detected, as blood biochemical indices (RBC, WBC, PLT, HGB, AST, ALT, BUN, and CREA) and H&E staining of major organs remained comparable to those of the control group throughout the observation period (Fig. S16–S17). These results provide comprehensive physicochemical characterization and in vivo biodistribution evidence supporting the translational potential of M0 macrophage-derived exosomes as a delivery platform for Antago-miR-155-5p in AD therapy. Therapeutic administration of Antago-miR-155-5p-loaded M0-Exos attenuates BAPN-induced aortic dissection progression Our results demonstrated that exosomal miR-155-5p from M1 macrophages promoted BAPN-induced AD through VSMC phenotypic switching by targeting SMAD5. Given previous reports of elevated serum miR-155-5p in AD patients, suggesting its potential as a diagnostic biomarker [41], we hypothesized that exosomal miR-155-5p promotes AD via regulation of SMAD5 and VSMC phenotype. To evaluate the therapeutic potential of targeting exosomal miR-155-5p in AD, we administered Antago-miR-155-5p-loaded M0-Exos to BAPN-induced AD mice via tail vein injection every 48 h from week 3 to week 7 (Fig. 12A). Treatment with Antago-miR-155-5p-Exos significantly improved survival compared with Antago-miR-NC-Exos (Fig. 12B). Gross morphological examination and high-frequency ultrasound imaging revealed that Antago-miR-155-5p-Exos markedly attenuated aortic dilation and reduced lesion severity (Fig. 12C and D). Quantitative analysis showed that both mortality and AD incidence were significantly lower in the Antago-miR-155-5p-Exos group (13.3% and 40%, respectively) compared with the control group (46.6% and 73.3%; Fig. 12E and F). Histological assessment further demonstrated that Antago-miR-155-5p-Exos preserved aortic wall integrity, reduced elastic fiber fragmentation, and decreased collagen deposition (Fig. 12G–I). Therapeutic administration of Antago-miR-155-5p-loaded M0-Exos attenuates BAPN-induced AD progression. A. Schematic timeline of the experimental design. BAPN-treated mice received tail vein injections of Antago-miR-NC-Exos or Antago-miR-155-5p-Exos (20 μg protein/150 μL) every 48 h from week 3 to week 7. B. Kaplan-Meier survival curves (n = 15 mice per group). C. Representative gross morphological images of whole aortas at week 7 (scale bar = 1 cm). D. Representative high-frequency ultrasound images of the thoracic aorta. Yellow arrows indicate the aortic lumen. E. Mortality rates (n = 15 mice per group). F. Incidence of AD (n = 15 mice per group). G. Semi-quantitative scoring of elastin fiber degradation (n = 15 mice per group). H. Time course of maximal aortic diameter measured by ultrasound from week 3 to week 7 (n = 15 mice per group). I. Representative histological images of aortic sections stained with H&E, EVG, and Masson's trichrome at week 7. Black arrows in EVG panels indicate fragmented elastic fibers. Scale bars: 200 μm (low magnification) and 20 μm (high-magnification insets). J. Western blot analysis of contractile markers (MYOCD, α-SMA, CNN, SM22α) and SMAD5 in aortic tissues. K. Quantification of relative protein expression from panel J (n = 3 independent experiments). L. Representative immunofluorescence images of SMAD5 (green) and SM22α (red) in aortic tissues. Nuclei were stained with DAPI (blue). Scale bar = 50 μm. Data are presented as mean ± SD. The survival curves in B were analyzed using the Kaplan-Meier curve and compared using the log-rank test. Data from other experiments were analyzed using an unpaired Student's t-test. ∗P < 0.05, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001. Western blot analysis of aortic tissues showed that Antago-miR-155-5p-Exos significantly upregulated the expression of contractile markers (MYOCD, α-SMA, CNN, SM22α) and SMAD5 compared with Antago-miR-NC-Exos (Fig. 12J and K). Immunofluorescence staining confirmed increased SMAD5 and SM22α expression in the aortic wall of mice treated with Antago-miR-155-5p-Exos (Fig. 12L and Fig. S18A-B). Collectively, these results demonstrate that therapeutic delivery of Antago-miR-155-5p via M0 macrophage-derived exosomes effectively attenuates BAPN-induced AD progression. This protective effect is associated with upregulation of SMAD5 and restoration of the VSMC contractile phenotype, accompanied by reduced elastic fiber degradation and vascular remodeling. These findings provide direct evidence supporting the therapeutic potential of targeting exosomal miR-155-5p in AD. Discussion Aortic dissection (AD) is a life-threatening cardiovascular condition characterized by acute aortic wall injury and high mortality [42]. Despite advances in surgical intervention, effective pharmacological therapies targeting the underlying molecular mechanisms remain limited [4]. In the present study, we provide comprehensive evidence that M1 macrophage-derived exosomes act as critical mediators in AD progression by transferring miR-155-5p to vascular smooth muscle cells (VSMCs). This leads to direct downregulation of SMAD5, activation of the RHOA/ROCK signaling pathway, and phenotypic switching of VSMCs from a contractile to a synthetic state, ultimately promoting aortic dilation, elastic fiber degradation, and disease progression. Conversely, therapeutic administration of Antago-miR-155-5p-loaded M0 macrophage-derived exosomes significantly attenuated these pathological changes, restored SMAD5 expression, and preserved the VSMC contractile phenotype, resulting in improved survival and reduced aortic pathology in the BAPN-induced AD model. Our mechanistic findings align with and extend previous reports implicating macrophage-derived exosomes in vascular remodeling diseases [43,44]. Earlier studies have shown that exosomes from polarized macrophages can influence endothelial and smooth muscle cell behavior in atherosclerosis and aneurysm models [27,36]. However, the specific role of exosomal miRNAs in AD has been less clearly defined. By integrating RNA sequencing, target prediction, luciferase reporter assays, and functional rescue experiments, we identified miR-155-5p as a key exosomal cargo that targets SMAD5. The observation that SMAD5 overexpression largely reversed the downregulation of contractile markers (MYOCD, α-SMA, CNN, SM22α) induced by miR-155-5p, and that this rescue effect was abolished by the ROCK inhibitor Y-27632, provides strong evidence that the SMAD5/RHOA/ROCK axis serves as a central signaling hub linking exosomal miR-155-5p to VSMC dysfunction. These results not only confirm the pro-synthetic effect of miR-155-5p in VSMCs but also highlight SMAD5 as a previously underappreciated regulator in AD pathogenesis. From a therapeutic perspective, our study demonstrates that engineered M0 macrophage-derived exosomes can serve as an effective delivery platform for nucleic acid therapeutics in AD. Compared with synthetic lipid nanoparticles (LNPs), which currently represent the most clinically advanced nucleic acid delivery system with mature manufacturing processes and established regulatory pathways, M0-Exos exhibited favorable biodistribution with detectable accumulation in the injured aorta [[45], [46], [47], [48], [49]]. This potential homing advantage, together with their inherent biocompatibility and low immunogenicity, positions exosome-based delivery as a promising alternative or complement to conventional nanoparticle systems in cardiovascular applications. However, LNPs still hold clear advantages in large-scale production, batch consistency, and regulatory approval [50,51]. We acknowledge that exosome-based therapeutics continue to face challenges in scalable manufacturing, standardization, and regulatory pathways. Future head-to-head comparative studies evaluating exosome-based versus LNP-based delivery of Antago-miR-155-5p in clinically relevant AD models will be essential to determine the optimal platform for clinical translation. A notable strength of this study lies in the rigorous experimental design addressing specificity concerns. While the exosome secretion inhibitor GW4869 provided initial evidence that blocking exosome release confers protection against AD, its broad action on multiple cell types limits conclusions regarding macrophage specificity [33]. By employing macrophage depletion with Clodrosome® [52]followed by rescue with purified M1-Exos, we were able to more directly demonstrate the pathogenic contribution of M1 macrophage-derived exosomes. This layered approach strengthens the causal link between specific exosome populations and disease progression, addressing a common limitation in exosome research where non-specific inhibitors are frequently used without further validation. Despite these advances, several limitations warrant consideration. Comprehensive characterization of exosomes, particularly in early experiments, relied on a limited set of markers. Although we subsequently incorporated multiple positive markers (CD9, CD63, TSG101) and negative markers, systematic comparison of exosomes derived from different macrophage polarization states or other myeloid cells remains incomplete [53]. Currently, there is a lack of well-validated surface markers to distinguish M0-versus M1-derived exosomes, with distinctions largely relying on functional outcomes and cargo profiles. Additionally, while primary BMDMs better reflect physiological conditions, we primarily used RAW264.7 cells for large-scale exosome production required for in vivo studies due to their rapid proliferation and high yield. Importantly, all key findings were validated in primary BMDMs with consistent results [26,27]. Additionally, the encapsulation efficiency of Antago-miR-155-5p achieved through electroporation was moderate (approximately 40–50%) [54], which may constrain therapeutic dosing and reproducibility across batches. While electroporation is a widely adopted technique, alternative loading methods such as sonication, extrusion, or parental cell transfection may offer improved efficiency and should be systematically evaluated in future work [55,56]. Furthermore, although macrophage depletion and exosome rescue experiments enhanced specificity [57], the potential systemic effects of broad exosome modulation on other physiological processes cannot be entirely excluded. Additionally, while DiR-labeled M0-Exos accumulated in the injured aorta, significant signals were also detected in the liver and spleen. Although no obvious toxicity was observed in blood biochemistry and organ histology up to 28 days, the long-term off-target effects of repeated administration of Antago-miR-155-5p-loaded exosomes warrant further investigation. Looking forward, several research directions emerge from this work. First, advanced proteomic and single-vesicle analytical approaches could facilitate the identification of more specific markers for macrophage subtype-derived exosomes, improving source traceability and reducing ambiguity in the field [58,59]. Second, optimization of loading strategies and the development of hybrid exosome-nanoparticle systems may enhance encapsulation efficiency while retaining the biological advantages of natural vesicles [60,61]. Third, surface engineering of exosomes through the incorporation of targeting peptides [62] or fusion proteins (such as Lamp2b) [63] represents a promising avenue to improve delivery specificity to VSMCs or macrophages and minimize off-target accumulation [64]. Finally, head-to-head comparative studies evaluating exosome-based versus lipid nanoparticle-based delivery of Antago-miR-155-5p in clinically relevant AD models will be critical for informing rational platform selection in future translational efforts [65]. These investigations will help address current technical limitations and accelerate the development of exosome-based therapeutics for aortic dissection and other cardiovascular diseases. Conclusion In conclusion, this study reveals that M1 macrophage-derived exosomal miR-155-5p promotes aortic dissection progression by suppressing SMAD5 and activating the RHOA/ROCK pathway in VSMCs. We further demonstrate that therapeutic delivery of Antago-miR-155-5p using M0 macrophage-derived exosomes can effectively counteract this pathogenic process by restoring SMAD5 expression and preserving the contractile phenotype of VSMCs. Through rigorous mechanistic validation, comprehensive exosome characterization, in vivo biodistribution analysis, and macrophage-specific rescue experiments, our work provides strong evidence supporting both the pathogenic role of M1-derived exosomes and the therapeutic potential of engineered M0-Exos in AD. These findings advance our understanding of exosome-mediated intercellular communication in vascular disease and establish M0 macrophage-derived exosomes as a promising platform for targeted nucleic acid delivery in cardiovascular disorders. Data availability statement The data that support the findings of this study are available from the corresponding author upon legitimate inquiry. Ethics approval and consent to participate All experimental procedures involving human tissue and animal subjects were consolidated and ethically approved separately: human specimen research was reviewed and authorised by the Ethics Committee of Zhongnan Hospital, Wuhan University (Approval No. 2023187), performed following the principles of the Declaration of Helsinki with written informed consent collected from all participants; all animal experiments were approved by the Institutional Animal Care and Use Committee of Zhongnan Hospital, Wuhan University (Approval No. ZN2023009) and implemented under specific pathogen-free (SPF) barrier conditions in full compliance with the authorised animal study protocols. Funding Financial support for this study was provided by the National Natural Science Foundation of China (Nos. 82470421 to LJP ) and the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (grant no. 2021-I2M-1-064 to SJP). Additional funding was received from the Central Universities’ Fundamental Research Funds (2042024kf0025 to LJP), the Hubei Provincial Key Research and Development Project (2023BCB002 to LJP), the Hubei Provincial Natural Science Foundation (No. 2022CFC026 to DZ), and the Hubei Province Health Commission (No. WJ2023M061 to DZ). CRediT authorship contribution statement Dengwei Cao: Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Validation, Writing – original draft. Xinyi Li: Data curation, Formal analysis, Funding acquisition, Methodology, Project administration, Resources, Software, Validation, Writing – original draft, Resources, Methodology. Shaoping Zhu: Formal analysis, Investigation, Project administration, Resources, Supervision, Visualization. Jianfeng Chen: Data curation, Formal analysis, Investigation, Resources, Supervision. Haoxiang Li: Formal analysis, Methodology, Software, Validation. Jiajun Shi: Methodology, Software, Validation, Visualization. Xiaoqi Xiong: Methodology, Validation. Jiahui Liu: Software. Yumou Wang: Software. Zhe Dong: Conceptualization, Formal analysis, Funding acquisition, Investigation, Supervision, Visualization, Writing – review & editing. Jiangping Song: Conceptualization, Data curation, Funding acquisition, Methodology, Project administration, Resources, Supervision, Visualization, Writing – review & editing. Jinping Liu: Conceptualization, Data curation, Formal analysis, Funding acquisition, Project administration, Resources, Supervision, Writing – review & editing. Declaration of competing interest We declare no competing financial or non-financial interests that could influence this work. Acknowledgements Dataset supporting the current research results can be obtained from the corresponding author on justifiable request. Footnotes Peer review under the responsibility of editorial board of Bioactive Materials. Supplementary data to this article can be found online at https://doi.org/10.1016/j.bioactmat.2026.05.057. Contributor Information Zhe Dong, Email: dongzhet0421123@163.com. Jiangping Song, Email: fwsongjiangping@126.com. Jinping Liu, Email: liujinping@znhospital.cn. Supplementary data The following are the Supplementary data to this article: Multimedia component 1 References Associated Data Supplementary Materials Multimedia component 1 Data Availability Statement The data that support the findings of this study are available from the corresponding author upon legitimate inquiry.